Evercore ISI Lowers Danaher (NYSE:DHR) Price Target to $226.00

Danaher (NYSE:DHR) had its price objective trimmed by Evercore ISI from $230.00 to $226.00 in a report published on Tuesday morning,Benzinga reports. The firm currently has an outperform rating on the conglomerate’s stock.

Other research analysts have also issued reports about the company. Wolfe Research lowered their price objective on Danaher from $275.00 to $220.00 and set an “outperform” rating for the company in a research report on Monday, April 7th. Stifel Nicolaus upgraded Danaher from a “hold” rating to a “buy” rating and set a $260.00 price target for the company in a research report on Friday, March 14th. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a research report on Friday, June 27th. The Goldman Sachs Group lowered their price target on Danaher from $260.00 to $240.00 and set a “neutral” rating for the company in a research report on Wednesday, April 23rd. Finally, JPMorgan Chase & Co. lowered their price target on Danaher from $280.00 to $260.00 and set an “overweight” rating for the company in a research report on Tuesday, April 22nd. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average price target of $248.00.

Danaher Price Performance

DHR stock opened at $200.70 on Tuesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.43 and a quick ratio of 1.05. The business has a 50 day simple moving average of $195.74 and a 200-day simple moving average of $206.85. The firm has a market capitalization of $143.63 billion, a PE ratio of 38.97, a price-to-earnings-growth ratio of 2.80 and a beta of 0.77. Danaher has a 1 year low of $171.00 and a 1 year high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.26. The company had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.58 billion. Danaher had a return on equity of 10.80% and a net margin of 15.81%. Equities research analysts anticipate that Danaher will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.64%. Danaher’s dividend payout ratio (DPR) is currently 24.85%.

Insider Buying and Selling at Danaher

In other news, Chairman Steven M. Rales sold 1,250,000 shares of the company’s stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the transaction, the chairman owned 3,105,808 shares of the company’s stock, valued at approximately $611,036,665.92. This represents a 28.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Christopher Paul Riley sold 15,805 shares of the company’s stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the sale, the executive vice president directly owned 15,179 shares in the company, valued at approximately $3,005,442. The trade was a 51.01% decrease in their position. The disclosure for this sale can be found here. 11.20% of the stock is currently owned by insiders.

Institutional Trading of Danaher

Several large investors have recently added to or reduced their stakes in the company. Norges Bank bought a new stake in shares of Danaher during the fourth quarter valued at approximately $2,130,740,000. Nuveen LLC bought a new position in Danaher in the first quarter valued at approximately $833,941,000. GAMMA Investing LLC boosted its stake in Danaher by 24,958.2% in the first quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate’s stock valued at $383,524,000 after acquiring an additional 1,863,381 shares during the last quarter. Two Sigma Advisers LP boosted its stake in Danaher by 4,248.8% in the fourth quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate’s stock valued at $376,347,000 after acquiring an additional 1,601,800 shares during the last quarter. Finally, Capital World Investors boosted its stake in Danaher by 32.7% in the fourth quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate’s stock valued at $1,460,215,000 after acquiring an additional 1,566,658 shares during the last quarter. 79.05% of the stock is owned by institutional investors.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.